Clinical trials: Gram-positive Bacterial Infections
Leprosy
Novel Interventions and Diagnostic Tests for Leprosy
Contact with Mycobacterium leprae (M. leprae) infected individuals is a risk factor for development of leprosy. Thus, detection of asymtomatically M.
- Trial name
- INDIGO#2 (NCT06222372)
- Testing
- Rifampin
- Where
- Bangladesh
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Annemieke Geluk
Diabetes Mellitus, Pulmonary Tuberculosis
Pulmonary Tuberculosis Patients With Diabetes Mellitus
The purpose of this study is to evaluate the effect of enhanced glycemic monitoring of diabetes upon diabetes glycaemic control during tuberculosis treatment in tuberculosis- diabetes patients.
- Trial name
- TANDEM (NCT02106039)
- Testing
- intensive monitoring
- Where
- 3 sites in Indonesia, Peru and 1 more
- Volunteers
- 350 people
- Sponsor
- Universitas Padjadjaran
Tuberculosis (TB), Tuberculosis Infection, Latent
Screening With Portable X-rays for Rapid Recognition of TB
SPOT-TB (Screening with Portable X-rays for rapid recOgniTion of TB) is a prospective study evaluating a community-based tuberculosis (TB) screening strategy for migrant populations in New York City.
- Conditions
- Tuberculosis (TB), Tuberculosis Infection, Latent, HIV (Human Immunodeficiency Virus)
- Trial name
- SPOT-TB (NCT07737275)
- Testing
- Mobile chest radiography for tuberculosis screening
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Infant, Newborn, Respiratory Insufficiency
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
This pilot study was a randomized, placebo-controlled, clinical trial to test the safety of using the intravenous form of Prostaglandin E1 (PGE1) in an inhaled form for treatment of hypoxemic respiratory failure in term newborns.
- Conditions
- Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn
- Trial name
- IPGE1 (NCT00598429)
- Testing
- Inhaled Prostaglandin E1
- Where
- 11 sites in United States
- Sponsor
- NICHD Neonatal Research Network
Tuberculosis, HIV
Assessing the Feasibility of Coach Mpilo for Men With TB and HIV
Men are less likely to report TB-related symptoms, get diagnosed, smear convert, or complete treatment, suggesting that outcomes along the TB cascade are worse for men.
- Trial name
- Coach Mpilo (NCT07117370)
- Testing
- Coach Mpilo
- Where
- South Africa
- Volunteers
- 240 people
- Sponsor
- Arizona State University
Bacterial Infections, Bone Diseases, Infectious
Fosfomycin I.v. for Treatment of Severely Infected Patients
The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin…
- Conditions
- Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
- Trial name
- FORTRESS (NCT02979951)
- Where
- 50 sites in Austria, Germany and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Tuberculosis
A Study of MVA85A in Healthy Infants
This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without tuberculosis or HIV infection.
- Trial name
- NCT00953927
- Testing
- MVA85A/AERAS-485, Candida Skin Test Antigen
- Where
- 3 sites in South Africa
- Volunteers
- 2,797 people, healthy volunteers welcome
- Sponsor
- Aeras
Diphtheria, Tetanus
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
This is a randomized cross-sectional study of the Swedish population. Blood samples will be collected from a subpopulation in order to estimate the age specific sero-prevalence of the Swedish population for diseases included in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- Sero 2007 (NCT00932269)
- Where
- Sweden
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Swedish Institute for Infectious Disease Control
Pneumococcal Pneumonia
Targeting of Immune Response After Pneumococcal Vaccination
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate…
- Trial name
- PncHR (NCT01402245)
- Testing
- Pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine
- Where
- 4 sites in Finland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Tuberculosis, Pulmonary
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIb trial to evaluate efficacy of RUTI® vaccine in DS- (Drug-Sensitive) and MDR-TB (Multidrug-resistant) patients favourably responding to…
- Trial name
- NCT04919239
- Testing
- RUTI®
- Where
- 2 sites in India
- Volunteers
- 140 people
- Sponsor
- Archivel Farma S.L.
Diphtheria, Tetanus
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS
The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- Venus (NCT02458183)
- Testing
- DTaP-IPV combination vaccine, DTaP vaccine and IPV vaccine
- Where
- 20 sites in South Korea, Thailand
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Tuberculosis, Meningeal, Linezolid
Pharmacokinetic Study of Linezolid for TB Meningitis
Tuberculosis meningitis (TBM) is the most severe manifestation of TB, resulting in death or neurological disability in up to 50% of affected patients, despite antibacterial treatment.
- Trial name
- SIMPLE (NCT03537495)
- Testing
- Linezolid
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Universitas Padjadjaran
Tuberculosis
Self-verification and Support Via Mobile Phones Drastically Improves Tuberculosis Treatment Success in LMIC Settings
Each year, 10.4 million patients are diagnosed with and 1.8 million people die from Tuberculosis (TB). Despite the availability of highly effective and accessible medications in the developing world where TB is endemic, the 6-18…
- Trial name
- NCT03135366
- Testing
- Keheala, Standard of Care
- Volunteers
- 1,190 people
- Sponsor
- Yale University
Tuberculosis
Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI
Tuberculosis (TB) continues to be the most important bacterial infection worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB. We are investigating a new skin test named C-Tb.
- Trial name
- NCT01631266
- Testing
- C-Tb, 2 T.U. Tuberculin PPD RT 23 SSI
- Where
- 13 sites in Spain
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Cartilage Diseases
Non-interventional Study With NOVOCART® Basic in Patients Treated for Cartilage Defects in the Knee With MAC
Retrospective, multicenter, single arm, non-interventional study to assess the safety and Performance of NOVOCART Basic and the clinical outcome of MAC with NOVOCART Basic in patients treated for cartilage defects in the knee.
- Trial name
- NBasic (NCT03808623)
- Testing
- MAC with NOVOCART Basic
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 41 people
- Sponsor
- Tetec AG
HIV Infection, Tuberculosis
Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment
This study investigates the prevention of early mortality in patients initiating antiretroviral therapy (ART) in sub-Saharan Africa where 79% of the co-infected cases of TB reside.
- Trial name
- PrOMPT (NCT01417988)
- Testing
- Experimental: Empiric TB treatment, ART only arm
- Where
- 3 sites in Gabon, Mozambique and 1 more
- Volunteers
- 44 people
- Sponsor
- Prof JMA Lange
Pulmonary Tuberculosis
Improving Community Based Tuberculosis Care in Ethiopia
The purpose of this study is to see if involving community health workers improves tuberculosis case finding and treatment outcome.
- Trial name
- community (NCT00803322)
- Where
- Ethiopia
- Volunteers
- 318 people
- Sponsor
- University of Bergen
Inflammatory Rheumatism, 18-FDG
Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica
Study of the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and comparaison with others inflammatories diseases.
- Conditions
- Inflammatory Rheumatism, 18-FDG, Positron-emission Tomography
- Trial name
- RHUMATEP (NCT06558357)
- Where
- France
- Volunteers
- 210 people
- Sponsor
- University Hospital, Brest
Drug Induced Hepatotoxicity, Tuberculosis
Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage
Purpose of the study is to evaluate the safety and efficacy of different re-introduction regimens in anti-TB drug induced liver damage. There is no consensus how best to treat such patients who developed drug induced liver damage.
- Trial name
- NCT00405301
- Testing
- Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
- Where
- 2 sites in India
- Volunteers
- 175 people
- Sponsor
- All India Institute of Medical Sciences
Tuberculosis
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
The objective of this study is to evaluate the safety and tolerability of single oral doses of TBA-354 when administered to healthy adult subjects.
- Trial name
- NCT02288481
- Testing
- TBA-354
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.